<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Pretreatment HIV drug resistance mutations among HIV-infected individuals with drug resistance</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>
     <italic>N</italic> (%)
    </th>
    <th>HIV drug resistance mutations, 
     <italic>N</italic> (%)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Total</td>
    <td char="(" align="char">117 (6.8)</td>
    <td/>
   </tr>
   <tr>
    <td>Non-nucleoside reverse transcriptase inhibitors (NNRTIs, any)</td>
    <td char="(" align="char">79 (4.6)</td>
    <td/>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>K103N/S/T,36 (2.1)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>V179D/E/T,28 (1.6)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>E138AA/K/G/Q,18 (1.1)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>V106M,9 (0.5)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>G190A/S,6 (0.4)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Y188L/C/F,6 (0.4)</td>
   </tr>
   <tr>
    <td>Efavirenz (EFV)
     <sup>a</sup>
    </td>
    <td char="(" align="char">76 (4.4)</td>
    <td>K101E,4 (0.2)</td>
   </tr>
   <tr>
    <td>Nevirapine (NVP)
     <sup>a</sup>
    </td>
    <td char="(" align="char">79 (4.6)</td>
    <td>Y181C,3 (0.2)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>H221Y,3 (0.2)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>A98G,2 (0.1)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>F227L,1 (0.06)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>L100I,1 (0.06)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>P225,1 (0.06)</td>
   </tr>
   <tr>
    <td>Nucleoside reverse transcriptase inhibitors (NRTIs, any)</td>
    <td char="(" align="char">38 (2.2)</td>
    <td/>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>K65R,9 (0.5)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>D67N,8 (0.5)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>M184I/V,7 (0.4)</td>
   </tr>
   <tr>
    <td>Emtricitabine (FTC)</td>
    <td char="(" align="char">12 (0.7)</td>
    <td>T215D/I/S,7 (0.4)</td>
   </tr>
   <tr>
    <td>Lamivudine (3TC)
     <sup>a</sup>
    </td>
    <td char="(" align="char">12 (0.7)</td>
    <td>K70E/R/T,5 (0.3)</td>
   </tr>
   <tr>
    <td>Abacavir (ABC)
     <sup>a</sup>
    </td>
    <td char="(" align="char">16 (0.9)</td>
    <td>L210W,4 (0.2)</td>
   </tr>
   <tr>
    <td>Didanosine (DDI)
     <sup>a</sup>
    </td>
    <td char="(" align="char">16 (0.9)</td>
    <td>K219R,2 (0.1)</td>
   </tr>
   <tr>
    <td>Stavudine (D4T)
     <sup>a</sup>
    </td>
    <td char="(" align="char">32 (1.9)</td>
    <td>L74LI,2 (0.1)</td>
   </tr>
   <tr>
    <td>Tenofovir (TDF)
     <sup>a</sup>
    </td>
    <td char="(" align="char">12 (0.7)</td>
    <td>M41L,2 (0.1)</td>
   </tr>
   <tr>
    <td>Azidothymidine (AZT)
     <sup>a</sup>
    </td>
    <td char="(" align="char">20 (1.2)</td>
    <td>T69D,2 (0.1)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>Y115F,2 (0.1)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>A62V,1 (0.06)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>V75I,1 (0.06)</td>
   </tr>
   <tr>
    <td>Protease inhibitors (PIs, any)</td>
    <td char="(" align="char">10 (0.6)</td>
    <td/>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>I47V,3 (0.2)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>I50V,2 (0.1)</td>
   </tr>
   <tr>
    <td>Atazanavir (ATV)</td>
    <td char="(" align="char">5 (0.3)</td>
    <td>I54V,2 (0.1)</td>
   </tr>
   <tr>
    <td>Darunavir (DRV)</td>
    <td char="(" align="char">4 (0.2)</td>
    <td>V82A/FI/L,2 (0.1)</td>
   </tr>
   <tr>
    <td>Lopinavir (LPV)
     <sup>a</sup>
    </td>
    <td char="(" align="char">10 (0.6)</td>
    <td>I84V,1 (0.06)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>L90M,1 (0.06)</td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>M46I/L,1 (0.06)</td>
   </tr>
   <tr>
    <td>Multi-drug resistance to NNRTI and NRTI</td>
    <td char="(" align="char">6 (0.4)</td>
    <td/>
   </tr>
   <tr>
    <td>Multi-drug resistance to NNRTI, NRTI and PI</td>
    <td char="(" align="char">1 (0.06)</td>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>a</sup> National free antiviral drugs in China
  </p>
  <p>
   <italic>HIV</italic> Human immunodeficiency virus, 
   <italic>NNRTI</italic> Non-nucleoside reverse transcriptase inhibitor, 
   <italic>NRTI</italic> nucleoside reverse transcriptase inhibitor, 
   <italic>PI</italic> Protease inhibitor
  </p>
 </table-wrap-foot>
</table-wrap>
